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Liver cirrhosis (LC) is the final usual outcome of liver damage induced by various chronic
liver diseases. Because of asymptomatic nature of LC, it is usually diagnosed at late
and advanced stages, and patients are easy to miss the best timing for treatment.
Thus, the early detection of LC is needed. In the prospective Korean Cancer Prevention
Study-II (K-II), we aimed to identify valuable biomarkers for LC using metabolomics to
distinguish subjects with incident LC (LC group) from subjects free from LC (control
group) during a mean 7-year follow-up period. Metabolic alterations were investigated
using baseline serum specimens acquired from 94 subjects with incident LC and 180
age- and sex-matched LC-free subjects via ultra-performance liquid chromatography
(UPLC)-linear-trap quardrupole (LTQ)-Orbitrap mass spectrometry (MS). As a result
of the metabolic analysis, 46 metabolites were identified. Among them, 11 and 18
metabolite level showed a significant increase and decrease, respectively, in the LC
group compared to the control group. Nine metabolic pathways, including glyoxylate
and dicarboxylate metabolism, amino acid metabolism, fatty acid metabolism, linoleic
acid metabolism, α-linolenic acid metabolism, and arachidonic acid metabolism, were
significantly different between the two groups. Logistic regression demonstrated that
the LC emergence was independently affected by serum levels of myristic acid, palmitic
acid, linoleic acid, eicosapentaenoic acid (EPA), lysophosphatidic acid (LPA) (18:1),
glycolic acid, lysophosphatidylcholine (lysoPC) (22:6), and succinylacetone (R2 = 0.837,
P < 0.001). This prospective study revealed that dysregulation of various metabolism
had the clinical relevance on the LC development. Moreover, myristic acid, palmitic acid,
linoleic acid, EPA, LPA (18:1), glycolic acid, lysoPC (22:6), and succinylacetone were
emerged as independent variables influencing the incidence of LC. The results support
that the early biomarkers found in this study may useful for predicting and remedying
the risk of LC.
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INTRODUCTION
Various chronic liver diseases induce liver damage, finally leading
to liver cirrhosis (LC) as the final common pathological outcome
(Zhou et al., 2014). The cause of LC includes alcoholism, chronic
hepatitis B (Asia-Pacific region) or C (western countries) virus
infection, and non-alcoholic fatty liver disease (Liaw et al.,
2008; Innes et al., 2013). Over early cirrhosis, the liver can
compensate the changes leaded by bridging fibrosis, and most
patients do not have any special symptoms unless entering the
decompensated cirrhosis stage (Qi et al., 2012). Decompensated
cirrhosis, also called end-stage liver disease, is a general factor of
global mortality; liver disease is the 7th and 12th cause of death
in Europe and United States, respectively (Peng et al., 2019). In
Korean population (aged 20–65), liver disease is the 8th leading
cause of overall death in 2017 (Korean Statistical Information
Service [KOSIS], 2018). Because of asymptomatic nature of LC,
LC is usually diagnosed at late and advanced stages and patients
often miss the best opportunity for therapy. Therefore, for
betterment of the diagnosis and prognosis, identifying additional
and reliable markers possibly used for early and accurate
detection of LC is necessary.
Metabolomics scientifically provides new aspects of disease
biomarker by analyzing biological samples and by offering
all detectable metabolites (metabolic profiling) (Jasbi et al.,
2019). Indeed, for observing metabolic alterations caused by
various disease, mass spectrometry-based metabolic profiling
is a good analytical platform (Jasbi et al., 2019); and this
technology is widely used to discover new biomarkers (Chen
et al., 2013; Lu et al., 2015). Researchers have attempted
to investigate metabolic profiling of LC, but the results
regarding pre-diagnostic biomarkers of LC are contradictory.
Furthermore, few studies have focused on prospective settings.
Therefore, in the prospective Korean Cancer Prevention Study-
II (KCPS-II), which enrolled a cancer-free cohort at baseline,
we applied metabolomics to distinguish individuals with LC
(LC group) from age- and sex-matched controls who were
free of LC (healthy controls) over a mean 7-year follow-up
period. Our objective was to identify early biomarkers with
value in differentiating these two groups using their baseline
serum metabolic profiles, as measured using ultra-performance
liquid chromatography (UPLC)-linear-trap quadrupole (LTQ)-
Orbitrap mass spectrometry (MS).
MATERIALS AND METHODS
Study Population
Study participants were recruited from the KCPS-II Biobank
during routine health check-up at 18 health promotion centers
in Seoul and Gyeonggi-do, South Korea (from 2004 to 2013).
Detailed information of the KCPS-II is described in a previous
publication (Jee et al., 2018). Inclusion criterion was normal
levels of liver enzymes, alanine aminotransferase (ALT) and
aspartate aminotransferase (AST), which reflect normal liver
function and hepatocyte damage, respectively; upper limits
of normal ALT were 34 and 24 U/L in men and women,
respectively, and upper limits of normal AST were 32 and
26 U/L in men and women, respectively. These values were set
according to a previous report for Koreans (Sohn et al., 2013).
Exclusion criteria were underweight or overweight/obesity
[18 kg/m2 ≤ body mass index (BMI) < 25 kg/m2]; hypertension
(systolic/diastolic blood pressure ≤ 140/90 mmHg); diabetes
(fasting glucose ≤ 126 mg/dL); alcohol abuse/alcoholic;
or any medication.
Among the 156,701 KCPS-II subjects, who were fully given
study explanation and provided written consent, 94 individuals
developed LC during the 7-year follow-up period (LC group);
at baseline, these individuals had had normal liver function and
no diagnostic evidences of LC during the health check-up. At
an approximately 1:2 ratio, 180 age- and sex-matched healthy
subjects (normal liver function at baseline and did not develop
LC during the 7-year follow-up period) were included as a control
group in the final analysis. The study, which complied with
the principle in the Declaration of Helsinki, was reviewed and
approved by the Institutional Review Board of Yonsei University.
Blood Collection and Biochemical and
Anthropometric Assessments
For all assessment, we used baseline serum samples to determine
any clinical and biochemical differences between the control and
LC groups prior to LC occurrence. For acquiring the serum
samples, peripheral venous blood was obtained after a fasting
period (minimum 12 h) from each study participants and the
serum was separated from the specimens. The serum aliquots
were then stored at –70◦C prior to further examination.
For biochemical assessments, fasting serum glucose, total
cholesterol, triglyceride, low-density lipoprotein (LDL)-
cholesterol, high-density lipoprotein (HDL)-cholesterol, AST,
ALT, and high-sensitivity C-reactive protein (hs-CRP) levels were
assessed via automatic analyzers. Each laboratory measurement
was carried out according to the internal and external quality
control (QC) procedures specified by the Korean Association of
Laboratory QC. The agreement for each measurement across
respective hospitals was high (correlation coefficients ranging
from 0.96 to 0.99) (Jee et al., 2014).
Regarding the anthropometric assessments, height (cm) and
body weight (kg) were measured with light clothing. To calculate
BMI, body weight (kg) was divided into height in meter squared
(m2). Waist circumference (cm) was measured midway between
the lower rib and the iliac crest. Systolic and diastolic blood
pressures (mmHg) were measured after a rest period of at
least 15 min. To gather smoking and alcohol consumption
histories, each study participants were interviewed with a
structured questionnaire.
Diagnosis of LC
From the National Health Insurance Service (NHIS), health
insurance claim information about LC incident were acquired.
Among the data obtained from the NHIS, patients who were
hospitalized and outpatients more than once were defined as
having LC. LC was coded as K74 according to the International
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Classification of Diseases, Tenth Revision (ICD-10) (World
Health Organization [WHO], 2011).
Non-targeted (Global) Metabolic Profiling
Using Serum
Sample Preparation and UPLC-LTQ-Orbitrap MS
Detailed description regarding a preparation of serum samples
was reported elsewhere (Jee et al., 2016). Briefly, 100-µL aliquots
of the baseline serum samples, obtained during the health
check-up, were mixed with acetonitrile (800 µL) by vortexing.
The mixtures were centrifuged (10,000 rpm, 5 min, 4◦C), and
then supernatant was dried with N2 gas. After drying process,
remaining pallet was dissolved in 10% methanol, vortexed, and
centrifuged (10,000 rpm, 5 min, 4◦C). The supernatant was then
transferred to a vial.
Full information of UPLC-LTQ-Orbitrap MS analysis was
also described in our previous research as a Supplementary
Material (Yoo et al., 2018). In brief, an Acquity UPLC-
BEH-C18 column (2.1 × 50 mm, 1.7 µm; Waters, Milford,
MA, United States) was equipped in a Thermo UPLC system
(Ultimate 3000 BioRS; Dionex-Thermo Fisher Scientific, Bremen,
Germany). The prepared samples were extracted and injected
(5 µL) into the column, and liquid chromatographic separation
was carried out in both electrospray ionization (ESI)-positive
and -negative modes. The metabolites, separated by the column
under each ESI-positive and -negative mode, were then applied to
an LTQ-Orbitrap MS (Thermo Fisher Scientific, Waltham, MA,
United States) operated in full scan mode for Fourier transform
MS. The spectra were gathered from m/z 50 to m/z 1,000. For
QC, a pooled QC sample was prepared and injected into every
5th sample. The metabolites’ MS/MS spectra were acquired by
applying a collision energy ramping from 20 to 55%.
Data Processing and Putative Identification of
Metabolites
A SIEVE 2.2 (Thermo Fisher Scientific, Waltham, MA,
United States) software was used to process relevant spectral data.
Analysis parameters were set as following: retention time width
2.5 min, m/z width 5 ppm and m/z range 50–1,000. Metabolites
were putatively identified by searching based on the databases:
ChemSpider1, Human Metabolome2, KEGG3, Lipid MAPS4, and
MassBank5. Selected metabolites were confirmed according to the
retention times and mass spectra of standard samples.
Statistical Analysis
As a statistic analysis tool, a SPSS version 23.0 (IBM/SPSS,
Chicago, IL, United States) was utilized. To compare nominal
and continuous variables between the two groups, a chi-squared
test and an independent t-test were conducted. To determine
independent effects of each variable on the LC incident, a
logistic regression analysis was performed. A two-tailed P-values
1http://www.chemspider.com/
2http://www.hmdb.ca/
3http://www.genome.jp/kegg/
4http://www.lipidmaps.org/
5http://www.massbank.jp/
less than 0.05 (P < 0.05) was thought to have statistical
significance. To avoid errors of multiple comparison with regard
to metabolites, P-values were adjusted by false discovery rate
(FDR); FDR-corrected q-values were calculated by a R package
“fdrtool” and q-values less than 0.05 (q < 0.05) were regarded as
having a statistical significance.
For a multivariate analysis, a SIMCA-P+ 14.0 (Umetrics Inc.,
Umeå, Sweden) was used to export spectrometric data. Pareto
scaling was used to all data prior to an in-depth analysis. To
analyze our models, as a supervised classification tool, orthogonal
projection to latent structures-discriminant analysis (OPLS-DA)
was used. The validity of the models was evaluated using Q2Y and
R2Y parameters. A metabolic pathway analysis was conducted by
MetaboAnalyst 3.06.
RESULTS
Baseline Clinical Characteristics
During the 7 years (mean follow-up period), 94 subjects emerged
LC among the 156,701 KCPS-II subjects. The 94 subjects with
incident LC were used as the LC group and 180 age- and
sex-matched healthy subjects (remained free from LC after the
follow-up) were set as the control group. After adjusting for
confounding factors (age, sex, BMI, and smoking and drinking
status), weight, waist circumference, systolic/diastolic blood
pressure, glucose, triglyceride, total cholesterol, HDL-cholesterol,
LDL-cholesterol, and hs-CRP did not show any statistical
significance between the two groups (Table 1). However, the
LC group showed slightly but significantly higher levels of AST
(P = 0.018), ALT (P = 0.030), and γ-glutamyltransferase (GGT)
(P = 0.022) than the control group. Moreover, the LC group
showed a trend toward a decrease in leukocyte number (white
blood cell; P = 0.057). Additionally, hepatitis B virus surface
antigen (HBsAg) and hepatitis C virus antibody (HCV Ab) as one
of the causes of LC were assessed at baseline and shown in the
Supplementary Table S1.
Metabolic Profiling in the Serum
Samples Using UPLC-LTQ-Orbitrap MS
Non-targeted (Global) Metabolic Pattern Analysis
Using an OPLS-DA score plots, both ESI-positive and -negative
ion modes chromatography data on serum metabolites were
analyzed. The quality of OPLS-DA was assessed by the values
of Q2Y and R2Y to evaluate the predictive ability of each model
and to confirm that the models were not over-fitted, respectively.
Figures 1A,B showed the results of comparisons of baseline
metabolite levels between the control and LC groups in ESI-
positive and -negative modes, respectively. The OPLS-DA models
displayed acceptable predictive ability and well fitted in ESI-
positive ion mode (Figure 1A; Q2Y = 0.732, R2Y = 0.877) and
ESI-negative ion mode (Figure 1B; Q2Y = 0.556, R2Y = 0.791).
The results indicated that the two groups could be
discriminated by discrepancies in amount of the metabolites. To
confirm potential metabolites providing the differences, S-plots
6http://metaboanalyst.ca/
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TABLE 1 | Clinical characteristics according to onset of liver cirrhosis (LC) in the
subjects with normal liver function.
Control group LC group Pa Pb
(n = 180) (n = 94)
Age (years) 45.2 ± 0.70 43.8 ± 0.99 0.270 –
Male/female n, (%) 110 (61.1)/69 (38.3) 57 (60.6)/37 (39.4) 0.763 –
Current smoker n,
(%)
40 (24.1) 23 (24.5) 0.904 –
Alcohol drinker n,
(%)
139 (82.7) 67 (71.3) 0.030 –
BMI (kg/m2) 23.2 ± 0.20 22.0 ± 0.18 <0.001 –
Weight (kg) 64.6 ± 0.77 60.7 ± 0.86 0.001 0.177
Waist
circumference (cm)
79.7 ± 0.67 78.7 ± 0.51 0.007 0.673
Systolic blood
pressure (mmHg)
116.2 ± 1.17 113.9 ± 1.08 0.143 0.537
Diastolic blood
pressure (mmHg)
72.9 ± 0.78 70.7 ± 0.87 0.073 0.894
Glucose (mg/dL)
∮
91.7 ± 1.48 87.5 ± 1.15 0.060 0.375
Triglyceride
(mg/dL)
∮ 128.8 ± 7.33 110.4 ± 7.26 0.184 0.764
Total cholesterol
(mg/dL)
∮ 186.0 ± 2.25 188.6 ± 3.04 0.456 0.260
HDL-cholesterol
(mg/dL)
∮ 52.3 ± 0.75 55.4 ± 1.30 0.039 0.241
LDL-cholesterol
(mg/dL)
∮ 111.4 ± 2.08 113.8 ± 2.72 0.398 0.205
AST (IU/L)
∮
19.5 ± 0.27 20.6 ± 0.41 0.022 0.018
ALT (IU/L)
∮
17.9 ± 0.45 19.0 ± 0.64 0.193 0.030
GGT (IU/L)
∮
25.1 ± 1.14 27.5 ± 1.86 0.280 0.022
White blood cell
(×103/UL)
∮ 5.74 ± 0.12 5.35 ± 0.13 0.035 0.057
hs-CRP (mg/dL)
∮
0.12 ± 0.02 0.20 ± 0.05 0.315 0.518
Mean ± SE.
∮
tested by logarithmic transformation. Pa-values derived from a chi-
squared test and an independent t-test for nominal variables and continuous
variables, respectively. Pb-values derived from an ANCOVA to adjust age, sex, BMI,
and smoking and drinking status.
of p(1) and p(corr)(1) were created for the OPLS-DA models
using Pareto scaling in ESI-positive and -negative ion modes
(Figures 1C,D). The S-plots showed that metabolites having
higher or lower values of p(corr) were more related to separate
between the control and the LC groups.
Baseline Serum Metabolites
Peaks (serum metabolites) that importantly discriminate
between the control and LC groups were selected in accordance
with the variable importance in the projection (VIP) values
(VIP ≥ 1.5). As comparing the metabolites, detected from the
baseline serum samples, between the two groups, a total of
156 metabolites (both ESI-positive and -negative ion modes)
had VIP values more than 1.5; of these, 46 metabolites were
putatively identified based on the metabolites’ database, whereas
the remaining were novel (Supplementary Figure S1). Table 2
presents the serum metabolites in the groups. In the LC
group, 18 metabolites had significantly lower peak intensities
than in the control group; glycolic acid (q = 1.112 × 10−11),
myristic acid (q = 0.019), 3-hydroxytetradecanedioic acid
(q = 0.025), α-linolenic acid (q = 1.877 × 10−5), linoleic acid
(q = 3.805 × 10−5), oleic acid (q = 0.025), 9-HOTE (q = 0.001),
13S-hydroxyoctadecadienoic acid (q = 3.326 × 10−5), 9-
cis-retinoic acid (q = 7.158 × 10−6), eicosapentaenoic acid
(q = 5.311 × 10−5), 5-HEPE (q = 3.021 × 10−6), 5-HETE
(q = 4.986 × 10−7), leukotriene B4 (q = 3.412 × 10−4),
17-HdoHE (q = 4.587 × 10−7), dehydroepiandrosterone
sulfate (q = 9.100 × 10−4), LPA (16:0) (q = 0.005), LPA (18:1)
(q = 2.097 × 10−5), and PE (P-16:0e) (q = 4.878 × 10−5).
On the other hand, compared to the control group, the LC
group showed 11 metabolites having significantly higher
peak intensities; succinylacetone (q = 3.242 × 10−10),
phenylalanine (q = 0.023), tyrosine (q = 0.004), indoleacrylic
acid (q = 2.931 × 10−6), tryptophan (q = 5.017 × 10−6),
palmitic acid (q = 0.043), palmitoylcarnitine (q = 8.624 × 10−4),
oleoylcarnitine (q = 7.053 × 10−4), lysoPC (16:0) (q = 0.006),
lysoPC (18:2) (q = 0.017), and lysoPC (22:6) (q = 0.026) (Table 2).
Metabolic Pathways Regarding the LC
Pathogenesis in Healthy Subjects
Via MetaboAnalyst 3.0, a web-based analysis module (see text
footnote 6), a metabolic pathway analysis was carried out to verify
the proper pathways associated with the selected metabolites
(Figure 2). Glyoxylate and dicarboxylate metabolism (glycolic
acid; impact = 0.007), tryptophan metabolism (tryptophan;
impact = 0.109), linoleic acid metabolism (linoleic acid
and 13S-hydroxyoctadecadienoic acid; impact = 0.656),
fatty acid metabolism (palmitoylcarnitine and palmitic acid;
impact = 0.030), phenylalanine, tyrosine and tryptophan
biosynthesis (tryptophan, tyrosine, and phenylalanine;
impact = 0.008), α-linolenic acid metabolism (α-linolenic
acid; impact = 0.203), arachidonic acid metabolism (5-
HETE, leukotriene B4, and arachidonic acid; impact = 0.226),
tyrosine metabolism (tyrosine; impact = 0.047), phenylalanine
metabolism (tyrosine and phenylalanine; impact = 0.119) were
relevant to incidence of LC (Table 3).
Logistic Regression Analysis
For evaluating independent influence of following variables on
LC incident, logistic regression analysis was performed: AST,
ALT, GGT, and 29 metabolites with q-values less than 0.05.
In all study participants, the incidence of LC was affected by
myristic acid, palmitic acid, linoleic acid, eicosapentaenoic acid,
LPA (18:1), glycolic acid, lysoPC (22:6), and succinylacetone
(R2 = 0.837, P < 0.001).
DISCUSSION
In present-day society, discovering biomarkers of LC is one
of the valuable goal to decrease mortality related to liver
disease. Although researchers have attempted to find LC-related
biomarker, there are still lack of prospective studies to identify
early biomarker of LC before its incident. In this study, total
29 metabolites showed the significant differences between the
control and LC groups at baseline (before LC incident); 11
and 18 metabolites had significantly increased and decreased
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FIGURE 1 | Comparison between serum metabolites in the control and Cirrhosis groups. (A) Score plots from OPLS-DA models classifying two groups in positive
mode. (B) Score plots from OPLS-DA models classifying two groups in negative mode. (C) S-plots for covariance [p] and reliability correlation [p(corr)] from
OPLS-DA models in positive mode. (D) S-plots for covariance [p(1)] and reliability correlation [p(corr)(1)] from OPLS-DA models in negative mode. (A,B) Comparison
between the baseline levels of the control group (free from cirrhosis at baseline and follow-up; n = 180) and the baseline levels of the cirrhosis group (free from
cirrhosis at baseline and incident cirrhosis at follow-up; n = 94).
peak intensities in the LC group, respectively, compared to the
control group. In addition, through the metabolomics technology
and metabolic pathway analysis, the present prospective study
suggested that deregulation of nine metabolic pathways showed
the clinical relevance on LC occurrence in subjects with
normal liver function and free from LC at baseline. Thus,
these metabolic processes’ alterations are possibly a potential
underlying mechanism on LC development. To discuss the
metabolites involved in the metabolic alteration regarding
incident of LC, we classified them by their type.
Amino Acids
In the present study, higher levels of phenylalanine, tyrosine,
and tryptophan in the LC group in comparison with the control
group definitely showed the alteration of amino acid metabolism.
These three amino acids are a member of aromatic amino acids
(AAAs) and they have been reported to increase in the serum
of hepatocellular carcinoma and LC patients (Gao et al., 2009;
Fages et al., 2015). While, branched chain amino acids (BCAAs),
including leucine, isoleucine, and valine have been informed to
decrease in the same condition, thus, an imbalance of the amino
acids has been revealed under the hepatocellular carcinoma and
LC condition (Gao et al., 2009; Fages et al., 2015). However, the
present metabolomics study showed that serum levels of BCAAs
were not significantly different between the control and the LC
groups. These findings may support the following pathologic
progression of LC: initially, BCAAs and AAAs are increased via
altered amino acid metabolism; and then, eventual degradation
of BCAAs may be occurred by carnitines, which oxidizes BCAAs
(Hoppel, 2003).
Acylcarnitines
Acyl group arising from the metabolism of BCAAs has been
suggested to be contributing proportionately to the acyl-
carnitine fraction in cirrhosis (Fuller and Hoppel, 1983).
During fatty acid oxidation, acylcarnitines are generated
as intermediates; and their accumulation is caused by
metabolic dysfunctions as a consequence of the insufficient
integration between β-oxidation and Krebs cycle (Al-Bakheit
et al., 2016). Long-chain acylcarnitines accumulate during
certain conditions including hepatic cirrhosis (Fuller and
Hoppel, 1983). Additionally, a new pilot study revealed
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TABLE 2 | Putative identification of serum metabolites according to onset of liver cirrhosis (LC) in the subjects with normal liver function.
m/z [M+H]† [M−H]‡ Molecular formula Putatively identified metabolites VIP t-test Cohen’s d Change trend
P q
75.009 C2H4O3 Glycolic acid‡ 7.885 3.109E-13 1.112E-11 −0.821 ↓
132.101 C6H13NO2 L-Leucine† 3.513 0.876 0.267 0.018 ↑
159.065 C7H10O4 Succinylacetone† 2.072 1.352E-11 3.242E-10 2.097 ↑
166.086 C9H11NO2 L-Phenylalanine† 3.803 0.033 0.023 0.257 ↑
182.081 C9H11NO3 L-Tyrosine† 2.486 0.004 0.004 0.340 ↑
188.070 C11H9NO2 Indoleacrylic acid† 1.861 6.461E-07 2.931E-06 0.601 ↑
205.096 C11H12N2O2 L-Tryptophan† 4.394 1.210E-06 5.017E-06 0.615 ↑
227.202 C14H28O2 Myristic acid‡ 2.385 0.026 0.019 −0.259 ↓
247.153 C12H22O5 3-Hydroxydodecanedioic acid† 1.961 0.123 0.067 −0.172 ↓
253.216 C16H30O2 Palmitoleic acid‡ 2.869 0.096 0.056 −0.202 ↓
255.233 C16H32O2 Palmitic acid‡ 9.512 0.070 0.043 0.236 ↑
275.185 C14H26O5 3-Hydroxytetradecanedioic acid† 2.186 0.037 0.025 −0.222 ↓
279.231 C18H30O2 α-Linolenic acid† 3.423 5.897E-06 1.877E-05 −0.493 ↓
279.233 C18H32O2 Linoleic acid‡ 8.057 1.383E-05 3.805E-05 −0.511 ↓
281.249 C18H34O2 Oleic acid‡ 7.365 0.037 0.025 −0.240 ↓
283.264 C18H36O2 Stearic acid‡ 3.644 0.803 0.250 0.030 ↑
295.226 C18H30O3 9-HOTE† 2.010 0.001 0.001 −0.355 ↓
295.227 C18H32O3 13S-Hydroxyoctadecadienoic acid‡ 2.400 1.167E-05 3.326E-05 −0.477 ↓
301.215 C20H28O2 9-cis-Retinoic acid† 3.109 1.842E-06 7.158E-06 −0.521 ↓
303.231 C20H30O2 Eicosapentaenoic acid† 3.694 2.079E-05 5.311E-05 −0.466 ↓
303.232 C20H32O2 Arachidonic acid‡ 4.486 0.497 0.172 −0.078 ↓
305.247 C20H34O2 11,14,17-Eicosatrienoic acid‡ 1.945 0.980 0.290 0.003 ↑
317.211 C20H30O3 5-HEPE‡ 1.809 6.711E-07 3.021E-06 −0.542 ↓
319.227 C20H32O3 5-HETE‡ 3.039 7.857E-08 4.986E-07 −0.589 ↓
327.232 C22H32O2 Docosahexaenoic acid‡ 4.894 0.143 0.075 −0.173 ↓
329.248 C22H34O2 Docosapentaenoic acid‡ 1.906 0.186 0.090 −0.158 ↓
335.222 C20H32O4 Leukotriene B4‡ 1.745 1.943E-04 3.412E-04 −0.404 ↓
343.227 C22H32O3 17-HdoHE‡ 3.320 7.074E-08 4.587E-07 −0.594 ↓
367.157 C19H28O5S Dehydroepiandrosterone sulfate‡ 1.847 6.909E-04 9.100E-04 −0.394 ↓
400.341 C23H45NO4 L-Palmitoylcarnitine† 1.618 6.438E-04 8.624E-04 0.518 ↑
409.236 C19H39O7P LPA (16:0)‡ 6.033 0.006 0.005 −0.325 ↓
426.356 C25H47NO4 Oleoylcarnitine† 2.161 4.898E-04 7.053E-04 0.498 ↑
433.236 C21H39O7P LPA (18:2)‡ 2.276 0.997 0.293 −4.360E-4 ↓
435.251 C21H41O7P LPA (18:1)‡ 3.459 6.726E-06 2.097E-05 −0.550 ↓
436.283 C21H44NO6P PE (P-16:0e)‡ 1.814 1.873E-05 4.878E-05 −0.467 ↓
468.307 C22H46NO7P LysoPC (14:0)† 1.765 0.127 0.069 0.195 ↑
480.343 C24H50NO6P LysoPC (P-16:0)† 2.471 0.404 0.146 0.116 ↑
494.322 C24H48NO7P LysoPC (16:1)† 2.040 0.760 0.240 0.037 ↑
496.338 C24H50NO7P LysoPC (16:0)† 6.143 0.007 0.006 0.351 ↑
510.353 C25H52NO7P LysoPC (17:0)† 1.781 0.429 0.153 0.106 ↑
518.322 C26H48NO7P LysoPC (18:3)† 1.620 0.361 0.134 −0.102 ↓
520.338 C26H50NO7P LysoPC (18:2)† 3.481 0.023 0.017 0.298 ↑
522.353 C26H52NO7P LysoPC (18:1)† 2.949 0.281 0.116 0.137 ↑
524.369 C26H54NO7P LysoPC (18:0)† 3.716 0.838 0.259 0.027 ↑
544.338 C28H50NO7P LysoPC (20:4)† 1.512 0.170 0.085 0.175 ↑
568.337 C30H50NO7P LysoPC (22:6)† 1.831 0.039 0.026 0.303 ↑
†Metabolites obtained by ESI-positive ion mode (M/Z [M+H]). ‡Metabolites obtained by ESI-negative ion mode (M/Z [M-H]). VIP is variable important in the projection.
P-values derived from an independent t-test between groups; control group (n = 180) and LC group (n = 94). q-Value is adjusted p-value that controls the false discovery
rate (FDR). Cohen’s d is an effect size for the comparison between two means; difference between two means divided by a pooled standard deviation; it is defined as
“small, d = 0.20,” “medium, d = 0.50,” and “large, d = 0.80,” Change trend is determined by a comparison of the metabolites’ peak intensities in the LC group with those
in the control group.
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FIGURE 2 | Metabolic pathway analysis. The “metabolome view” presents pathways arranged according to the scores based on enrichment analysis (y axis) and
topology analysis (x axis). The color and size of each circle is based on P-values and pathway impact values, respectively.
TABLE 3 | Metabolic pathway analysis.
Metabolic pathways Hits P FDR Impact
Glyoxylate and dicarboxylate metabolism Glycolic acid 6.11.E-09 1.22.E-07 0.007
Tryptophan metabolism L-Tryptophan 2.36.E-06 1.57.E-05 0.109
Linoleic acid metabolism Linoleic acid 3.58.E-06 1.79.E-05 0.656
13S-Hydroxyoctadecadienoic acid
Fatty acid metabolism L-Palmitoylcarnitine 1.08.E-04 4.31.E-04 0.030
Palmitic acid
Phenylalanine, tyrosine and tryptophan biosynthesis L-Tryptophan 3.37.E-04 8.43.E-04 0.008
L-Tyrosine
L-Phenylalanine
α-Linolenic acid metabolism α-Linolenic acid 3.82.E-04 8.49.E-04 0.203
Arachidonic acid metabolism 5-HETE 0.001 0.002 0.226
Leukotriene B4
Arachidonic acid
Tyrosine metabolism L-Tyrosine 0.009 0.012 0.047
Phenylalanine metabolism L-Tyrosine 0.018 0.022 0.119
L-Phenylalanine
Hits: the actually matched metabolites uploaded in MetaboAnalyst 3.0. FDR: the P-values adjusted using false discovery rate (FDR). Impact: the pathway impact value
calculated from pathway topology analysis.
that in patients with hepatocellular carcinoma, serum
acylcarnitines had high concentration compared to normal
subjects (Yaligar et al., 2016). In this study, even before
LC development, the LC group showed higher levels of
palmitoylcarnitine and oleoylcarnitine than the control group.
Both palmitoylcarnitine and oleoylcarnitine are long-chain
acylcarnitines formed from long-chain fatty acid [palmitic
acid (C16:0) and oleic acid (C18:1), respectively,] (Kuhajda
et al., 1994), therefore, our results are in agree with the studies
previously mentioned.
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Saturated Fatty Acids
In this study, in comparison with the control group, the
levels of palmitic acid (C16:0) and myristic acid (C14:0) were
higher and lower in the LC group, respectively. Palmitic acid
(C16:0) is reported to induce lipoapoptosis in hepatocytes via
mechanisms, including mitochondrial dysfunction and stress of
endoplasmic reticulum (Martínez et al., 2015). Myristic acid
(C14:0), which is more rapidly metabolized (both β-oxidation
and elongation) in hepatocyte than palmitic acid (C16:0) (Rioux
et al., 2000), has been known not to be lipotoxic unlike palmitic
acid (C16:0); however, a recent study reported a synergistic
effect of myristic acid (C14:0) in palmitic acid (C16:0)-induced
lipotoxicity (Martínez et al., 2015). In the present study, lower
levels of myristic acid (C14:0) observed in the LC group might
be due to its rapid metabolism in hepatocyte; and the rapid
metabolism might contribute to accumulation of palmitic acid
(C16:0) in the LC group. Furthermore, the logistic regression
analysis revealed the independent effect of myristic acid (C14:0)
and palmitic acid (C16:0) on LC progression and metabolic
pathway analysis showed that palmitic acid (C16:0) involved in
fatty acid metabolism which altered in the LC group. These
findings, therefore, suggest that early changes in these fatty acids
need to be observed to prevent LC development.
Polyunsaturated Fatty Acids
α-Linolenic acid (C18:3, ω-3 PUFA) is a major precursor of ω-
3 PUFA metabolites. In this study, the levels of α-linolenic acid
(C18:3) and its downstream ω-3 PUFA metabolites, including
eicosapentaenoic acid (C20:5), docosapentaenoic acid (C22:5),
and docosahexaenoic acid (C22:6), were lower in the LC group
than the control group; however, docosapentaenoic acid (C22:5)
and docosahexaenoic acid (C22:6) did not show significant
differences. Studies have shown that reduction of circulating
levels of ω-3 PUFAs is observed in cirrhotic patients (Watanabe
et al., 1999; Ristic´-Medic´ et al., 2013; Enguita et al., 2019). In
addition, especially, depletion of docosahexaenoic acid (C22:6)
may influence on homeostasis of liver tissue, likely fibrosis
progression (Enguita et al., 2019). In the present study, the reason
why the LC group had lower levels ofω-3 PUFAs than the control
group was hard to know because of limited information. Factors
of ω-3 PUFAs deficient could be diverse. First of all, ω-3 PUFAs
are essential fatty acids which cannot be synthesized in the body
and therefore have to be consumed from diet; thus, a lack of
ingestion of ω-3 PUFAs may be a potential reason. Other factors,
including malabsorption and changes in microbiota, also can
be a reason related to altered circulation levels of ω-3 PUFAs
(Enguita et al., 2019). Conclusionally, since the LC group showed
a decrease ofω-3 PUFA levels even before LC incident, our results
suggest that low levels ofω-3 PUFAs should be carefully observed
for preventing future risk of LC development.
In case of ω-6 PUFA, the LC group also showed a significant
decrease in linoleic acid (C18:2) compared to the control
group. The levels of 13S-hydroxyoctadecadienoic acid, which
is a lipoxygenation product derived from linoleic acid (C18:2)
(The Human Metabolome Database [HMDB], 2019), was also
significantly lower in the LC group. Meanwhile, the levels of
arachidonic acid (C20:4), converted from linoleic acid (C18:2),
did not show any statistical difference between the groups. There
are conflicting reports on the levels of ω-6 PUFAs. A study
revealed that arachidonic acid (C20:4) levels showed marked
decrease in patients with hepatitis, cirrhosis, and liver cancer
compared to healthy controls (Safaei et al., 2016). On the other
hand, high ω-6 PUFA to ω-3 PUFA ratio induced by large
amount of consumption of ω-6 PUFAs is observed in liver
diseases (Wree et al., 2013); and a study demonstrated that high
intake of ω-6 PUFAs should be avoid for mitigating progression
of liver disease due to their pro-inflammatory characteristics
(Ullah et al., 2019). The LC group of this study had low
levels of ω-6 PUFAs rather than the control group before LC
development; in addition, the inflammatory marker, hs-CRP, was
not statistically different between the groups. Thus, inflammation
caused by ω-6 PUFAs may not be a principal reason of future LC
progression in this study.
Arachidonic Acid (C20:4) and
Eicosapentaenoic Acid (C20:5)-Related
Metabolites
5-HETE and leukotriene B4 are metabolites associated with
arachidonic acid (C20:4) metabolism. Arachidonic acid (C20:4)
released by phospholipases from cell membrane is metabolized
by lipoxygenases (LOX); especially, 5-LOX generates 5-HETE
and leukotriene B4 from arachidonic acid (C20:4) (Harizi et al.,
2008). These two metabolites induce chemotactic response
and chemokinesis of leukocytes and show increased levels in
inflammatory lesions for immune function, therefore, 5-HETE
and leukotriene B4 may play a key role on leukocyte function
(Goetzl et al., 1982). In the present study, leukotriene B4 and
5-HETE levels were significantly lower in the LC group than
the control group and the leukocyte number in the LC group
had a trend toward decrease compared to the control group.
This result corresponds to a previous research that LC subjects
showed significant downregulated levels of eicosanoids including
leukotriene in comparison with healthy controls (Fitian et al.,
2014). Thus, relatively low leukocyte number, which may be
associated with low levels of 5-HETE and leukotriene B4, may
lead to an improper inflammatory/immune function against
future LC progression.
Meanwhile, 5-HEPE is also a metabolite processed by
5-LOX from eicosapentaenoic acid (C20:5) (Onodera et al.,
2017). A study demonstrated that eicosapentaenoic acid
(C20:5) and 5-HEPE have anti-inflammatory effects on chronic
inflammation disease including hepatic steatosis by enhancing
anti-inflammatory immune cells, such as T regulatory cells
(Onodera et al., 2017). In addition, 5-HEPE lessens inflammatory
reaction of macrophage through the JNK pathway and has
a protection effect against hepatic steatosis (Wang et al.,
2017). Therefore, these metabolites can be considered as an
effective factor for preventing early stage of liver disease (before
progression of LC). In the present study, both eicosapentaenoic
acid (C20:5) and 5-HEPE were significantly lower in the LC group
than the control group; moreover, the former was revealed as an
independent factor for incidence of LC. Thus, eicosapentaenoic
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acid (C20:5) and 5-HEPE may become a potent biomarker for
prediction LC development.
LysoPCs
LysoPC is a metabolite released from phospholipids by
phospholipase A2, an enzyme that involves in hydrolysis the
ester bond of sn-2 position in phospholipids (Kokotou et al.,
2017). This metabolite has been reported to be associated with
oxidative stress and inflammation (Zhang et al., 2019), which are
related to a progression of liver diseases; oxidative stress has been
well known to play important role in liver diseases and chronic
inflammation also has been revealed to result in liver fibrosis,
cirrhosis, and hepatocellular carcinoma by causing persistent
liver injury (Yuan et al., 2019). Indeed, many studies proved that
lysoPCs are connected with liver damage. Kakisaka et al. (2012)
demonstrated that lysoPCs lead to hepatocyte lipoapoptosis that
is germane to liver diseases via various mechanism. Other studies
showed that greater concentration of lysoPC in hepatic tissue
are observed in non-alcohol steatohepatitis patients compared to
healthy controls (Puri et al., 2007; Han et al., 2008). Finally, Yang
et al. (2014) showed that lysoPCs were identified as a potential
biomarker for early diagnosis of liver fibrosis and cirrhosis. In
the current study, the levels of lysoPCs (16:0, 18:2, and 22:6) were
detected to be significantly higher in the LC group compared to
the control group at baseline. Therefore, our results can support
the role of lysoPC as an early biomarker for LC.
From lysoPC species, lysophosphatidic acids (LPAs)
are generated by enzymes, autotaxin (ATX) which has
lysophospholipase D activity (Kremer et al., 2010). Several studies
have been demonstrated that ATX-LPA axis is an important
pathological pathway regarding liver diseases (Nakagawa et al.,
2011; Erstad et al., 2017; Valdés-Rives and González-Arenas,
2017). In addition, a study showed that elevated serum levels of
ATX are positively associated with the severity of LC; and the
ATX has a positive correlation with LPA levels in liver cirrhotic
patients (Pleli et al., 2014). Unlikely these studies, however,
our data showed decreased levels of LPA (16:0 and 18:1) in the
LC group. This discordance may come from disease status of
individuals. In this study, the time point at which biological
samples obtained of the LC group was before LC occurrence,
whereas the studies mentioned previously measured the markers
under disease existence. Perhaps, the increase of lysoPC levels
may precede the LPA elevation in a pathologic progression of
LC. Moreover, lysoPC (22:6) and LPA (18:1) were revealed as
independent factors for future LC incident via logistic regression
analysis. Thus, lysoPC increase and LPA decrease may need to be
carefully observed before LC incident.
Other Metabolites
Glycolic acid and succinylacetone were also revealed as
independent factors associated with the incidence of LC in
the present study. In the liver, glycolic acid is generated
from ethylene glycol by enzymes, alcohol dehydrogenase and
aldehyde dehydrogenase; and then is metabolized to oxalic acid
by enzymes, glycolate oxidase and glycolate dehydrogenase.
Eventually, oxalic acid is excreted in urine via kidney (Corley
et al., 2005). Glycolic acid and oxalic acid have been reported to
cause metabolic acidosis and acute renal failure (Yamamoto et al.,
2011; Tuero et al., 2018). Although our study detected glycolic
acid in the LC group, the levels were lower than the control group
and their clinical relevance on the liver has not been focused so
far. Thus, an attempt to elucidate relationships between glycolic
acid and future LC development is needed.
Succinylacetone is a metabolite of tyrosine and has liver
toxicity. Fumarylacetoacetate hydrolase (FAH) plays a key role
in tyrosine metabolism to produce succinylacetone; and FAH
deficiency mainly induced by a heredity problem of FAH
encoded gene leads to type 1 tyrosinemia, in which increased
levels of succinylacetone are observed along with liver diseases
including hepatic failure, LC, and liver cancer (Scott, 2006; Yang
et al., 2017). In addition to succinylacetone, levels of tyrosine,
methionine, and phenylalanine also have been reported to
increase in genetic deficiency of FAH-induced type 1 tyrosinemia
(Scorza et al., 2014). Although, in the present study, there
were no participants with congenital type 1 tyrosinemia caused
by FAH gene abnormality, not only succinylacetone but also
tyrosine and phenylalanine levels showed significant elevated
levels in the LC group compared to the control group. There
are limits to know an exact mechanism with our information,
however, we suggest a possibility based on our findings:
activities of tyrosine metabolism-related enzymes may be altered
before LC development.
The present study has limitations. First, even though we
obtained the information of LC occurrence from the NHIS record
(K74 according to the ICD-10), an exact cause of LC in each
subject is still ambiguous; because we did not directly review the
patients’ charts and carry out standardized test for LC diagnosis.
In addition, depending on which cause or underlying disease
leaded to the onset of LC, the metabolic profile at baseline
might be possible to vary slightly. Nonetheless, in this study, LC
was a final phenotype after all; accordingly, our data can warn
about a future risk of LC development. Second, notably, in this
study, the exposure assessment was performed at a single time
point (baseline; before LC incident) and changes which might be
occurred during the follow-up were not measured although the
follow-up period was long (7 years); therefore, exact mechanisms
on future LC development cannot be fully elucidate with our
metabolomics data interpretation. Third, an external validation
of our result with an independently different cohort should have
performed; however, due to the limitation of available resources
(funding, samples, time, etc.), it could not be possible. Instead,
we have reviewed carefully our metabolomics data to support
their pathological relevance on LC development. Lastly, diurnal
variations might exist among the study subjects because sample
collection time was varied (a.m. or p.m.). For remedying the
shortcomings, further study is needed.
CONCLUSION
Despite these limitations, still, many studies can support
our results and vice versa. Similar to previous metabolomics
studies, the clinical relevance of deregulations of amino acid
metabolism, linoleic acid metabolism, fatty acid metabolism,
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α-linolenic acid metabolism, and arachidonic acid metabolism
were observed. In addition, myristic acid, palmitic acid,
linoleic acid, eicosapentaenoic acid, LPA (18:1), glycolic acid,
lysoPC (22:6), and succinylacetone were revealed as the
independent variables related to the future LC development.
Metabolic patterns found in this study before LC progression
provide meaningful and potential biomarkers for future LC
development. The results can provide pathological insight
of LC incident and the biomarkers may be useful in early
diagnosis of LC.
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